MedTrace Logo

Expanded Access Neoantigen Vaccine in Solid Tumors

NCT03914872 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2024-03-12

No results posted yet for this study

Summary

This is an expanded access use study. Safety data will be collected from participants.

Conditions

  • Solid Tumor, Adult

Interventions

BIOLOGICAL

Neoantigen DNA Vaccine

The schedule for vaccination will be weeks 1, 5, 9, 13, 17, and 21. All vaccines will occur within +/- 1 week with at least 3 weeks between vaccines.

DEVICE

Integrated electroporation device

* Ichor Medical Systems * All study injections will be given intramuscularly using an integrated electroporation device

Sponsors & Collaborators

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • William E Gillanders, M.D. · Washington University School of Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03914872 on ClinicalTrials.gov